Mann D, Boguschewski K D, Brämer U, Dobritz H, Hitzeroth T
Z Gesamte Inn Med. 1979 Apr 1;34(7):192-5.
224 patients with coronary heart disease, hypertension, disturbances of cardiac rhythm or hyperkinetic heart syndrome were treated with the cardioselective beta-blocker Talinolol (Cordanum) for a period up to 3 years. In 239 examinations in intravenous or peroral application of this medicament we controlled among others the appearance of side effects. This test was carried out with the help of standardised questionings and clinical controls. Apart from registrations of ECG and blood pressure clinico-chemical investigations were included and in the long-term experiment also tests by dermatologists, otorhinolaryngologists and ophthalmologists. In the total number of patients the proportion of side appearances was 17,6%, in the long-term experiment (100 patients with on an average 12.9 months) 7%. The symptoms most frequently cited in the initial phase, such as fatigue, weakness, insomnia and nausea receded within 4 weeks apart from few exceptions. There did not appear any essential bradycardic disturbances of the cardiac rhythm, just as little were references to disadvantageous reactions in the sense of a practolol syndrome.
224例冠心病、高血压、心律失常或运动亢进性心脏综合征患者接受心脏选择性β受体阻滞剂他林洛尔（Cordanum）治疗，疗程长达3年。在239次静脉或口服该药的检查中，我们尤其对副作用的出现情况进行了监测。该试验借助标准化询问和临床检查进行。除了记录心电图和血压外，还进行了临床化学检查，在长期试验中，皮肤科医生、耳鼻喉科医生和眼科医生也参与了检查。在所有患者中，副作用出现的比例为17.6%，在长期试验（100例患者，平均治疗12.9个月）中为7%。在初始阶段最常提及的症状，如疲劳、虚弱、失眠和恶心，除少数例外，在4周内都有所缓解。未出现任何严重的心律失常性心动过缓，也几乎没有关于心得宁综合征意义上的不良反应的报告。
